Previous Close | 2.2000 |
Open | 2.2000 |
Bid | 2.1600 x 1100 |
Ask | 2.1800 x 1100 |
Day's Range | 2.1400 - 2.2200 |
52 Week Range | 1.6500 - 3.7800 |
Volume | |
Avg. Volume | 174,954 |
Market Cap | 152.81M |
Beta (5Y Monthly) | 1.23 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9460 |
Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.70 |
Subscribe to Yahoo Finance Plus to view Fair Value for OVID
The big shareholder groups in Ovid Therapeutics Inc. ( NASDAQ:OVID ) have power over the company. Institutions will...
Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the second half of 2022 Presented preclinical data from six animal models reinforcing the seizure-reducing potential of OV329 at two leading epilepsy research meetings Ended the second quarter 2022 with cash, cash equivalents and marketable securities of $152.4 million, expected to support the advancement of its epilepsy pipeline into 2025 NEW YORK, Au
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...